MicroIslet gets grant for islet transplant technology:
This article was originally published in Clinica
The US National Institutes of Health has given MicroIslet a $120,000 cash boost to further develop its islet cell transplantation technology for treating insulin-dependent diabetes. The phase I small business innovation research (SBIR) grant will support efforts in islet isolation process development and process automation and will be performed in parallel to current safety and efficacy studies, said the San Diego, California firm. It entitles MicroIslet to compete for up to $750,000 in phase II SBIR funding.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.